Distinguished Graduate Alumni Award
Presented every year to an alumnus/a from the College of Medicine's Ph.D. or M.S. program who has demonstrated outstanding achievement in basic, clinical or applied research; education; industry; public service/humanitarianism; and/or outstanding commitment to the College of Medicine community.
2018 Distinguished Graduate Alumni Award Winner
Nicholas Heintz, M.S. '77, Ph.D. '79
Dr. Heintz is a respected leader in graduate education and within the Departments of Pathology and Laboratory Science and Microbiology and Molecular Genetics at the University of Vermont. After postdoctoral training at the University of Virginia, he began his career as a professor of pathology at UVM in 1983, before receiving a secondary appointment to the Department of Microbiology and Molecular Genetics in 1992. He transitioned to professor emeritus in 2014.
His research focuses on cell signaling pathways that control cell cycle progression, cell survival, and cell death, particularly in cancer cells, and his work has been published in over 100 peer-reviewed journal articles, book chapters and invited reviews. He has presented his research at many other Universities and a wide range of scientific meetings. Dr. Heintz’ research has made him an integral member of the UVM Cancer Center since 1987. In his lab, he has trained more than ten doctoral students, seven postdoctoral fellows and numerous undergraduate students.
His leadership extends beyond scientific endeavors, and his impact on graduate education at the University has been sustained over many years. He chaired the Graduate College Executive Committee, and has served as member of numerous departmental and Graduate College committees. From 2013 to 2015, he served as the director of the Cellular, Molecular and Biomedical Sciences Graduate Program, the largest interdisciplinary graduate program in the biosciences at UVM.
2017 Distinguished Graduate Alumni Award Winner
David Warshaw, Ph.D. '79
Dr. David Warshaw has pursued a renowned career as a biomedical scientist, teacher, and mentor during more than 40 years at the University of Vermont.
His research has focused on muscle contractility, starting with research on blood vessels while a doctoral student at UVM. As a postdoctoral fellow he accomplished a major technical feat -- the first measurements of the contractile properties of single smooth muscle cells. After establishing his own laboratory at UVM in 1983, his research evolved to the study of individual molecular motor proteins (myosin); pioneering the use of state-of-the-art techniques, including single molecule motility assays and laser traps. With these new approaches he was able to measure the force generated by a single motor molecule, and thereby provided new insights into the fundamental properties of the contractile machinery of muscle as documented in his 125 peer-reviewed publications.
In 1995 Dr. Warshaw became chair of the Department of Molecular Physiology and Biophysics, and recruited a number of outstanding scientists in the molecular motor and protein structure and function fields. With these colleagues and other external collaborators, he developed a National Institutes of Health funded Program Project Grant (PPG), which was renewed three times. This PPG centered on translating the fundamental insights of motor proteins into understanding genetic forms of cardiac hypertrophy and heart failure. Dr. Warshaw has received several prestigious awards. He is an Established Investigator of the American Heart Association (AHA) and a Fellow of both the AHA and Biophysical Society. He became a University Scholar in 1999 and in the same year was inducted into the Vermont Academy of Science and Engineering. He has served on numerous editorial boards and study sections, and organized numerous international symposia. In 2014, he was named to the Board of Directors of the Cardiovascular Research Institute of Vermont. Dr. Warshaw has taught undergraduate, graduate, and medical students, and has mentored over 25 graduate students and postdoctoral fellows, many of whom have gone on to successful careers in academia.
2016 Distinguished Graduate Alumni Award Winner
Anne E. Hout, M.S. '88, Ph.D. '90
Dr. Anne Huot has dedicated her career to the transformative power of education and the opportunities higher education presents for contributing to and bettering society. Throughout her 23 year experience as a faculty member and senior administrator, and now as president of Keene State College, Dr. Huot has focused her attention on academic excellence as her highest priority. Her work has been directed toward developing systems and programming that encourage and support student learning and success, and preparation for active citizenship and meaningful careers. To her role as president of Keene State College, Dr. Huot brings a vision that is informed by her experience as a first generation college student, a native of New Hampshire, and an educator with extensive background in public higher education. She believes passionately in the need for accessibility to higher education for all students and the unique role, mission, and opportunities provided by institutions of public higher education. Her history as a faculty member and academic leader demonstrate her commitment to these values. From 2007 to 2013, she served as provost and vice-president for academic affairs at The College at Brockport, State University of New York, during which time she created an Office for Diversity, established a School of Business and Graduate School, and revised the general education program to introduce interdisciplinary teaching and learning. She has also served as associate provost and executive vice provost for the Office of Academic Affairs, State University of New York-System Administration in Albany, and she was a member of the University of Vermont faculty for fourteen years, including serving in the role of Graduate College executive dean. She has said that her training as a scientist informs her work as a university leader, allowing her to see problems from multiple angles, test hypotheses, and use data to inform decision making.
2015 Distinguished Graduate Alumni Award Winner
Patrick Y-K Wong, Ph.D. '75
Dr. Wong received his Ph.D. in biochemistry from UVM in 1975. He went on to have a distinguished career as a pioneer in elucidating the role of prostaglandins in inflammation, cardiovascular disease and cancer. Dr. Wong was also a Fogarty Senior International Research Fellow with Nobel Laureate Professor Bengt Samuelsson at the Karolinska Institutet, Stockholm, Sweden. He is a Professor Emeritus of the Department of Pharmacology at New York Medical College and Chairman, CEO of BioProst Pharmaceuticals. Dr. Wong is an inspired choice for this award. He is an example of someone who was educated here at UVM and has continued to extend the scientific boundaries in his field. He is a reminder that one’s education never really ends – that getting a Ph.D. or any other degree is really just the beginning for those who bring intellect and curiosity and determination
with them to the laboratory every day.
Since earning his doctorate in biochemistry here at UVM in industry leadership. His pioneering research on biosynthesis and metabolism of prostaglandins led to his later work on the role of lipid mediators in inflammation, apoptosis and cancer. For more than 30 years, his research in eicosanoids and clinical pharmacology was supported by the National Institutes of Health, the American Heart Association, and others. He has more than 135 publications in peer-reviewed journals. He was invited twice as visiting professor at the Karolinska Institute in Nobel laureate Bengt Samuelsson’s laboratory -- the first time before Bengt won the Nobel Prize. In 2001, he was the recipient of the Karolinska Institute Research Medal. He joined the faculty of New York Medical College in 1979, leaving in 1994 to become professor and chair of cell biology at the University of Medicine and Dentistry of New Jersey. He returned to New York Medical College in 2002 and became Professor Emeritus in 2005. Dr. Wong has extensive experience in the pharmaceutical industry. In 2001 he founded Bioprost Pharmaceuticals, LLC, in the United States and continues to serve as its Chairman. He is a sought-after advisor and innovator, and is currently engaged in a large biomedical research and clinical project in China that has significant collaborative opportunities worldwide. He also founded Nobel Forum, USA, a non-profit organization to promote the advances of science and medicine in China and around the world. And this impressive journey started, in large measure, here on the UVM College of medicine campus.
Peter Paradiso, Ph.D. '77
Dr. Paradiso recently retired as Vice President, new business and scientific affairs for Pfizer Vaccines, a Division of Pfizer, Inc. In this position, he was responsible for global scientific affairs and strategic planning within the vaccine research and development group and for commercial oversight of products in development. He has worked in the field of vaccine development for the past 28 years. Dr. Paradiso has published broadly in the field of pediatric vaccines, especially in the areas of glycoconjugates, combination vaccines and respiratory viral vaccines. He has been involved in the development and the global registration of many major vaccines.
Dr. Paradiso served as a member of the National Vaccine Advisory Committee (NVAC) and is currently a member of the Advisory Council on Immunization for New York State and a liaison member of the CDC's Advisory Committee on Immunization Practices. He has also served as an advisor to the WHO's Strategic Advisory Group of Experts on vaccines and to the GAVI Task Force on Research and Development.
Prior to his graduate degree, he earned a B.S. in chemistry from St. Lawrence University.
James Aiken, Ph.D.’70
James Aiken is President and Chief Executive Officer of Keystone Symposia on Molecular and Cellular Biology, a 40-year-old, educational nonprofit organization that annually conducts 50 to 60 biomedical conferences attended by about 14,000 scientists. Prior to his work with Keystone Symposia, Dr. Aiken had a distinguished career spanning 32 years as a research scientist and research executive in the pharmaceutical industry. He was Senior Director of Therapeutic Area Strategy for Pharmacia Corporation in Peapack, NJ until the company was acquired by Pfizer in 2003. Before that he was Director of Biology in Stockholm and Uppsala for the Swedish branches of Pharmacia & Upjohn, Director of Metabolic Diseases Research for the Upjohn Company in Kalamazoo, Michigan and held various research positions at Upjohn in the areas of atherosclerosis, thrombosis, and diabetes. At Eli Lilly and Company in Indianapolis, he conducted research in the field of smooth muscle function, as it relates to vascular biology and hypertension as well as uterine physiology and parturition.
Dr. Aiken has received numerous honors and served on committees influencing research direction. He was a long term member of the Pharmacology Advisory Committee of the Pharmaceutical research and Manufactures Association Foundation; a former member of the Board of Directors and on various committees of the Michigan Affiliate of the American Heart Association; a member of the Swedish Foundation for Strategic Research Boards for Cardiovascular Diseases and Biopolymers and Biocompatible Materials. He was an adjunct Professor of Pharmacology at Michigan State University and adjunct Assistant Professor of Medicine at Indiana University School of Medicine. In 1998 he received a Graduate College Alumni Scholar Award from the University of Vermont. He is currently on the Board of Directors of the Global Food Protection Institute. Dr. Aiken received his undergraduate degree in Biology from Dartmouth College in 1965 and his Ph.D. in Pharmacology from the University of Vermont in 1970.
David Lyden, M.D.,Ph.D. ’86
David Lyden is a pediatric neuro-oncologist at Memorial Sloan-Kettering Cancer Center. He holds a joint appointment at Weill Cornell Medical College and is the Stavros S. Nairchos Chair and Associate Professor of Pediatrics and Cell and Developmental Biology. Dr. Lyden has made several fundamental discoveries which involve the role of bone marrow-derived stem and progenitor cells in tumor vasculogenesis and in metastasis. He and his colleagues showed the first evidence of genetic regulation in vasculogenesis with the discovery of one family of genes called Id1-4 in early blood vessel development in embryogenesis and in tumorigenesis. His laboratory was the first to identify two bone marrow-derived cells, endothelial progenitor cells (EPCs) and hematopoietic progenitor cells (HPCs) that participate in the formation of new blood vessels in primary tumors. In recent years, his team has shown evidence that secreted factors from primary tumors prime certain tissues for tumor cell engraftment. In response to these secreted factors, tumor associated cells such as hematopoietic progenitor cells cluster at ‘pre-metastatic niches’, creating an environment which is conducive for tumor cell adhesion and invasion. At the pre-metastatic niche, newly recruited myeloid cells collaborate with other cells types residing in the tissue parenchyma. Together, these cells provide a platform of chemokines, growth factors, matrix-degrading enzymes and adhesion molecules that accelerate metastatic niche formation. This model suggests that systemic therapies targeted to the metastatic microenvironment should be used early in treatment of tumors. Most recently, he has found that tumor-secreted microparticles, known as exosomes, induce bone marrow progenitor cells and pre-metastatic niche cells towards a pro-metastatic phenotype (Nature 1999, 2001, 2005, Nature Reviews Cancer 2009 & Nature Medicine 2012.)
Dr. Lyden’s honors and awards include: Distinguished Alumnus Brown University (2003) and the Leonard Weill Memorial Lecturer Award (2007). His work was highlighted in “Nature Milestones: Cancer”. In 2007, he was awarded a Presidential Medical Distinction Bial Award by President Cavaco Silva of Portugal. He is Co-Senior Editor for “Cancer Metastasis: Biologic Basis and Therapeutics”, the first cancer metastasis textbook published by Cambridge University Press (April 2011), and has been featured as one of fifteen cancer experts in the book ‘Why Millions Survive Cancer: The Successes of Science” (author: Lauren Pecorino, Oxford Univ. Press). He is also the recipient of the 2011 Duke University Residency Alumni Award and Lecture. He will be honored for his work in metastasis as recipient of the Inaugural I.J. “Josh” Fidler Innovation in Metastasis Research Award, given by the Metastasis Research Society and Anti-Cancer Inc., USA at the International Metastasis Research Society Meeting in Brisbane, Australia in September 2012. Dr. Lyden was educated at the, University of Vermont (PhD 1986), Brown University (MD 1989), Duke University (Residency) and Memorial Sloan-Kettering Cancer Center (Fellowship).
2010 Brooke T. Mossman, M.S. '70, Ph.D. '77
2005 Mark Brann, PhD ’85